Plaque Psoriasis
📧 Sign up to get email alerts when something new happens for Plaque Psoriasis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-08-23Clinical Trial Update: Safety and Tolerability of Repeat Courses of IM Alefacept [Phase 3]
Phase 3 trial update on safety and tolerability of repeat courses of IM Alefacept in chronic plaque psoriasis.
-
FDA approval · 2023-08-11FDA Approved: LEXETTE — Original Application (Mayne Pharma)
FDA approved Mayne Pharma's original application for halobetasol propionate under the brand LEXETTE.
-
CLINICAL_TRIALS trial_result · 2023-08-08Clinical Trial Update: Multi-Dose Study of SHR-1314 in Subjects With Moderate-to-severe Plaque Psoriasis [Phase 1, Phase 2]
Clinical trial update for SHR-1314 in moderate-to-severe plaque psoriasis, across Phase 1 and Phase 2, and the study is completed.
-
FDA approval · 2023-07-24FDA Approved: COSENTYX — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approved a supplemental application for Cosentyx (secukinumab) submitted by Novartis Pharmaceuticals Corporation.
-
CLINICAL_TRIALS trial_result · 2023-07-21Clinical Trial Update: Comparative Study of BAT2206 With Stelara® in Patients With Moderate to Severe Plaque Psoriasis [Phase 3]
A Phase 3 comparative study of BAT2206 versus Stelara® in moderate to severe plaque psoriasis has completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2023-07-19FDA Approved: SILIQ — Supplemental Application (Bausch Health US LLC)
FDA approved a supplemental application for SILIQ (brodalumab) filed by Bausch Health US LLC.
-
FDA approval · 2023-07-19FDA Approved: ADALIMUMAB-ADBM — Supplemental Application (QUALLENT PHARMACEUTICALS HEALTH LLC)
The FDA approved a supplemental application for ADALIMUMAB-ADBM, a biosimilar of adalimumab from Quallent Pharmaceuticals Health LLC.
-
CLINICAL_TRIALS trial_result · 2023-07-06Clinical Trial Update: Adrenal Suppression and Absorption Study of Halobetasol Propionate Foam in Subjects 12-17 With Plaque Psoriasis [Phase 4]
Phase 4 trial updating Adrenal suppression and absorption of halobetasol propionate foam in adolescents with plaque psoriasis; results poste…
-
FDA approval · 2023-06-30FDA Approved: ADALIMUMAB-ADBM — Supplemental Application (QUALLENT PHARMACEUTICALS HEALTH LLC)
The FDA approved a supplemental application for the adalimumab biosimilar ADALIMUMAB-ADBM from Quallent Pharmaceuticals Health LLC.
-
FDA approval · 2023-06-14FDA Approved: ABRILADA — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved a supplemental application for ABRILADA (adalimumab-afzb) submitted by Pfizer Laboratories Div Pfizer Inc to update the labelin…
-
CLINICAL_TRIALS trial_result · 2023-06-08Clinical Trial Update: A Study to Evaluate ABY-035 in Subjects With Moderate-to-severe Plaque Psoriasis [Phase 2]
A Phase 2 clinical trial evaluating ABY-035 in subjects with moderate-to-severe plaque psoriasis has completed.
-
CLINICAL_TRIALS trial_result · 2023-06-07Clinical Trial Update: Outcome of Treatment With Secukinumab in the Treatment of Moderate to Severe Plaque Psoriasis at Tertiary Care Hospital. [Phase 4]
A Phase 4 clinical trial evaluating the outcome of secukinumab treatment in moderate to severe plaque psoriasis completed at a tertiary care…
-
CLINICAL_TRIALS trial_result · 2023-06-05Clinical Trial Update: A Study to Compare the Efficacy and Safety of CT-P43 to Stelara in Patients With Plaque Psoriasis [Phase 3]
A Phase 3 trial comparing CT-P43 to Stelara in patients with plaque psoriasis has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2023-05-25Clinical Trial Update: Pharmacokinetics, Efficacy, Safety, and Immunogenicity of SB5 Versus Humira in Subjects With Moderate to Severe Chronic Plaque Psoriasis [Phase 4]
Phase 4 trial update comparing SB5 to Humira in adults with moderate to severe plaque psoriasis, focusing on pharmacokinetics, efficacy, saf…
-
FDA approval · 2023-05-23FDA Approved: ADALIMUMAB — Original Application (CELLTRION USA, Inc.)
FDA approved ADALIMUMAB-AATY from CELLTRION USA, Inc. as a biosimilar to adalimumab under an Original Application for the same indications a…
-
FDA approval · 2023-05-18FDA Approved: ADALIMUMAB-ADBM — Supplemental Application (QUALLENT PHARMACEUTICALS HEALTH LLC)
FDA approved a supplemental application for ADALIMUMAB-ADBM, a biosimilar to adalimumab, from QUALLENT PHARMACEUTICALS HEALTH LLC.
-
FDA approval · 2023-04-25FDA Approved: TAZAROTENE — Original Application (Padagis Israel Pharmaceuticals Ltd)
FDA approved the original ANDA for tazarotene (TAZAROTENE) by Padagis Israel Pharmaceuticals Ltd.
-
FDA approval · 2023-04-14FDA Approved: ADALIMUMAB — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for adalimumab-adaz, a biosimilar to adalimumab, confirming its regulatory approval for use.
-
CLINICAL_TRIALS trial_result · 2023-04-12Clinical Trial Update: A Phase Ⅲ Study to Evaluate Tildrakizumab in the Treatment of Chinese Subjects With Moderate to Severe Plaquetype Psoriasis [Phase 3]
Phase 3 study evaluating tildrakizumab for moderate to severe plaque psoriasis in Chinese patients has completed.
-
FDA approval · 2023-03-31FDA Approved: YUSIMRY — Supplemental Application (Coherus BioSciences Inc)
FDA approved a supplemental Biologics License Application for YUSIMRY (adalimumab-aqvh) by Coherus BioSciences, authorizing the biosimilar p…
-
CLINICAL_TRIALS trial_result · 2023-03-28Clinical Trial Update: Adrenal Suppression and Pharmacokinetics of Topicort® Spray, 0.25% in Pediatric Patients With Plaque Psoriasis [Phase 4]
Phase 4 trial updating on adrenal suppression and pharmacokinetics of Topicort Spray 0.25% in pediatric plaque psoriasis patients; results p…
-
CLINICAL_TRIALS trial_result · 2023-03-21Clinical Trial Update: A Study of the Safety and Efficacy of Risankizumab in Adult Participants With Plaque Psoriasis Who Have Had a Suboptimal Response to Secukinumab or Ixekizumab [Phase 3]
Phase 3 study evaluating risankizumab in adults with plaque psoriasis who had suboptimal response to secukinumab or ixekizumab; study comple…
-
CLINICAL_TRIALS trial_result · 2023-03-21Clinical Trial Update: A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3) [Phase 3]
Phase 3 long-term study of LY3074828 in moderate-to-severe plaque psoriasis was terminated; results posted in 2023.
-
FDA approval · 2023-03-20FDA Approved: TAZAROTENE — Original Application (Solaris Pharma Corporation)
The FDA approved a generic version of tazarotene (topical retinoid) from Solaris Pharma Corporation through an Original Abbreviated New Drug…
-
CLINICAL_TRIALS trial_result · 2023-03-10Clinical Trial Update: Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-216) [Phase 2]
Phase 2 clinical trial completed evaluating maximal usage pharmacokinetics and safety of ARQ-151 in children with plaque psoriasis.